We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
+28.6%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$879K
Cap. Flow
-$3.68M
Cap. Flow %
-2.43%
Top 10 Hldgs %
97.11%
Holding
17
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$3.22M
2
TRML
Tourmaline Bio
TRML
+$460K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$46.2M 30.53%
6,068,125
– –
VRNA
2
DELISTED
Verona Pharma
VRNA
$34.8M 22.99%
1,332,485
– –
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.69B
$26.1M 17.22%
1,025,000
– –
GLUE icon
4
Monte Rosa Therapeutics
GLUE
$1.4B
$11.2M 7.4%
1,472,331
– –
ACRS icon
5
Aclaris Therapeutics
ACRS
$726M
$6.84M 4.52%
434,455
-200,000
-32% -$3.22M
BMEA icon
6
Biomea Fusion
BMEA
$84.6M
$6.73M 4.45%
798,757
– –
PSTX
7
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$5.53M 3.65%
1,043,267
– –
NUVB icon
8
Nuvation Bio
NUVB
$2.2B
$4.88M 3.22%
2,541,009
– –
ELEV
9
DELISTED
Elevation Oncology
ELEV
$2.69M 1.78%
2,834,910
– –
OKUR
10
OnKure Therapeutics
OKUR
$154M
$2.06M 1.36%
88,608
– –
SPRB
11
Spruce Biosciences
SPRB
$118M
$1.32M 0.87%
16,073
– –
MRKR icon
12
Marker Therapeutics
MRKR
$18.8M
$849K 0.56%
314,286
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$8.54B
$761K 0.5%
67,646
– –
TECX
14
Tectonic Therapeutic
TECX
$529M
$717K 0.47%
84,148
– –
VIRX
15
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$421K 0.28%
288,571
– –
BCEL
16
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$311K 0.21%
387,653
– –
TRML
17
DELISTED
Tourmaline Bio
TRML
– –
-17,500
Closed -$460K

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Aisling Capital Management held 17 positions worth $151M, up 0.58% from $151M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Aisling Capital Management's Q4 2022 filing shows 1 reduced and 1 closed positions. The largest sale was Aclaris Therapeutics, an estimated $3.22M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Aisling Capital Management's biggest Q4 2022 reduction was Aclaris Therapeutics, cutting an estimated $3.22M.
  • Aisling Capital Management fully exited Tourmaline Bio in Q4 2022, selling an estimated $460K.
  • Aisling Capital Management's ten largest holdings make up 97% of its $151M portfolio in Q4 2022.
  • Aisling Capital Management opened 0 new positions and closed 1 in Q4 2022.
  • Aisling Capital Management's portfolio value rose 0.58% quarter-over-quarter to $151M.

Based on Aisling Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.